Splenomegaly is a marker of advanced chronic liver disease and portal hypertension in HIV infection
HIV Medicine · 2023-03 · 24 (3) · 366-371
DOI: 10.1111/hiv.13390 ↗Kurz gefasst
Fachartikel in der Zeitschrift HIV Medicine, online erschienen am 30.08.2022. Verfasst von Dana Kablawi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Québec, Canada. Hauptthemen laut MEDLINE: HIV Infections, Hypertension, Portal, Elasticity Imaging Techniques. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: FRQS.
Abstract (Originalsprache)
Objectives
To evaluate the clinical significance of splenomegaly as a marker of underlying liver disease in people with HIV (PWH).
Methods
We included consecutive PWH from a prospective cohort from 2010 to 2020 with available liver stiffness measurement (LSM) and liver imaging to define splenomegaly (> 13 cm) within 1 year. Cut‐offs of LSM > 10 kPa and > 21 kPa were used to identify advanced chronic liver disease (ACLD) and portal hypertension, respectively. Logistic regression multivariable analysis was employed to identify independent predictors of ACLD.
Results
In all, 331 PWH were included, 76% of them men, with a median (interquartile range) age of 51.3 (45–58) years, all receiving antiretroviral treatment, and 53% were HIV monoinfected. The PWH with splenomegaly exhibited a higher prevalence of ACLD compared with those with normal spleen size, as per LSM (26% vs. 9%; p = 0.009). Portal hypertension diagnosed by LSM was also more prevalent in PWH with splenomegaly than in those without (15% vs. 2%; p < 0.001). Independent predictors of ACLD were viral hepatitis coinfection [adjusted odds ratio (aOR) = 3.15, 95% confidence interval (CI): 1.65–6.0], lower platelets (aOR = 0.99, 95% CI: 0.99–0.99) and splenomegaly (aOR = 2.41, 95% CI: 1.17–4.99). In patients with available oesophagogastroduodenoscopy, splenomegaly was also associated with higher prevalence of oesophageal varices and other endoscopic findings of portal hypertension (38% vs. 17%; p = 0.027).
Conclusions
Splenomegaly identified on routine imaging may have utility as a marker of ACLD and portal hypertension, prompting further investigations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Québec, Canada.
- Division of Experimental Medicine, McGill University, Montreal, Québec, Canada.
ORCID-Profile: Giada Sebastiani
Förderung
- FRQS
Zitieren
APA
Kablawi, D., Alhinai, A., Wong, P., Deschenes, M., Sebastiani, G., & Benmassaoud, A. (2023). Splenomegaly is a marker of advanced chronic liver disease and portal hypertension in HIV infection. HIV Medicine, 24(3), 366-371. https://doi.org/10.1111/hiv.13390
Vancouver
Kablawi D, Alhinai A, Wong P, Deschenes M, Sebastiani G, Benmassaoud A. Splenomegaly is a marker of advanced chronic liver disease and portal hypertension in HIV infection. HIV Medicine. 2023;24(3):366-371. doi:10.1111/hiv.13390
BibTeX
@article{Kablawi2023,
author = {Kablawi, Dana and Alhinai, Alshaima and Wong, Philip and Deschenes, Marc and Sebastiani, Giada and Benmassaoud, Amine},
title = {Splenomegaly is a marker of advanced chronic liver disease and portal hypertension in HIV infection},
journal = {HIV Medicine},
year = {2023},
volume = {24},
number = {3},
pages = {366--371},
doi = {10.1111/hiv.13390}
}
EUVIMED